Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2022

Product sales, net

Schedule of Disaggregation of Revenues

During the years ended December 31, 2022, 2021 and 2020, the Company recorded product sales, net, as follows:

	Year Ended December 31,
(In thousands)	2022		2021		2020
VIVITROL	$	379,478	$	343,853	$	310,722
ARISTADA and ARISTADA INITIO		302,052		275,356		241,038
LYBALVI		96,022		8,215		—
Total product sales, net	$	777,552	$	627,424	$	551,760

Manufacturing and royalty revenues

Schedule of Disaggregation of Revenues

During the years ended December 31, 2022, 2021 and 2020, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

	Year Ended December 31, 2022
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	115,655	$	115,655
VUMERITY		32,493		83,003		115,496
RISPERDAL CONSTA		42,670		7,243		49,913
Other		37,211		13,708		50,919
	$	112,374	$	219,609	$	331,983

	Year Ended December 31, 2021
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	303,106	$	303,106
VUMERITY		25,808		61,614		87,422
RISPERDAL CONSTA		40,413		10,456		50,869
Other		39,407		61,003		100,410
	$	105,628	$	436,179	$	541,807

	Year Ended December 31, 2020
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products (1)	$	—	$	274,200	$	274,200
VUMERITY		8,848		13,693		22,541
RISPERDAL CONSTA		56,893		14,468		71,361
Other		53,293		62,605		115,898
	$	119,034	$	364,966	$	484,000

(1) “Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).